JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational results posting revenues of $167 million, a 27% rise over prior year levels.

These modules allow the ProteinReDiff framework to capture intricate protein–ligand interactions, improve the fidelity of binding affinity predictions and enable more precise redesigns of ligand ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a price target ...